Free-paper-session-header---EN

New free paper sessions added to Congress program

The WFH 2024 World Congress is just a few weeks away, and we’re happy to announce that ten new free paper sessions have been added to the program. The sessions will showcase top-scoring abstracts submitted by experts in the field. Take part in these sessions and delve into groundbreaking research across a variety of disciplines.

Also available in: Français Español

At the WFH 2024 World Congress, the free paper sessions will feature authors presenting their abstracts as an oral presentation, followed by a Q&A period. The sessions will cover a wide range of topics, including the following:

To find out more about all the free paper sessions on offer at the WFH 2024 World Congress, click here.

Don’t miss the Christine Lee Young Researcher Award sessions

Established in 2012 by the WFH and Wiley, the Christine Lee Young Researcher Award is given in recognition to a top young researcher (graduate student or postdoctoral fellow) who is the primary author and presenter of a highly rated submitted abstract in any discipline involving hemophilia or other related bleeding disorders. A prize of $3,000 for the best free paper presentation and a prize of $1,000 for the best poster presentation, along with a three-year online personal subscription to Haemophilia, will be awarded to two deserving young researchers.

Authors will compete for the Christine Lee Award in the three sessions below.

The winners will be announced at the closing plenary on Wednesday, April 24, 2024 (16:30 to 17:00 CEST).

April 23, 2024, 11:30 to 12:30

  • Fitusiran displays efficient pro-hemostatic activity in a mouse model of inducible factor X-deficiency, Geneviève McCluskey, France
  • Evaluating the impact of the Self-BAT screening tool on referral outcomes. Results of the “Let’s Talk Period” project, Laura McDonald, Canada
  • The lower double negative T cells proportion predicted the better high-titer inhibitors eradication outcomes of immune tolerance induction, Zhengping Li, China
  • Bleeding profile and quality of life and women and girls with hemophilia, von Willebrand disease (VWD) and rare bleeding disorders, Nita Radhakrishnan, India

April 22, 10:45 to 11:30

  • Better cost-effective outcome of intermediate-dose immune tolerance induction for severe hemophilia A children with high-titer inhibitors in developing countries: the interim report of a randomized multicenter clinical trial in China, Runhui Wu, China
  • Towards tailoring the use of emicizumab for hemophilia A children in China: a retrospective clinical data from a comprehensive care center of China, Qianqian Mao, China
  • Comparing desmopressin response classifications in 149 children with von Willebrand disease, Michael Shu, Canada

April 22, 15:15 to 16:00

  • PRO management and collection outside clinical research: why is it so difficult?, Laura González-Rodríguez, Spain
  • Effects of resistance training on muscle strength in adults with hemophilia: a systematic review and meta-analysis, Rodrigo Núñez-Cortés, Chile
  • Final efficacy of adjunctive rituximab combined with low-dose immune tolerance induction in hemophilia A patients with inhibitor, Zekun Li, China
  • Use of recombinant von Willebrand factor concentrate for peri-partum hemostatic management of women with type 2 VWD; a case series, Ozlem Turan, U.K.

Learn more about what the WFH 2024 World Congress has to offer by consulting the detailed program here. To find out more about Congress, please click here.

We’ve accomplished a lot this year, we need your help to continue strong.

Would you like to read more about similar articles?

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.